EP1175504A4 - Dna, welche für den menschlichen vanilloid-rezeptor vr1 kodiert - Google Patents

Dna, welche für den menschlichen vanilloid-rezeptor vr1 kodiert

Info

Publication number
EP1175504A4
EP1175504A4 EP00922143A EP00922143A EP1175504A4 EP 1175504 A4 EP1175504 A4 EP 1175504A4 EP 00922143 A EP00922143 A EP 00922143A EP 00922143 A EP00922143 A EP 00922143A EP 1175504 A4 EP1175504 A4 EP 1175504A4
Authority
EP
European Patent Office
Prior art keywords
dna encoding
vanilloid receptor
human vanilloid
human
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00922143A
Other languages
English (en)
French (fr)
Other versions
EP1175504A1 (de
Inventor
Adrienne Dubin
Mark Erlander
Kathryn E Rogers
Arne Huvar
Rene Huvar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Publication of EP1175504A1 publication Critical patent/EP1175504A1/de
Publication of EP1175504A4 publication Critical patent/EP1175504A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
EP00922143A 1999-04-15 2000-04-13 Dna, welche für den menschlichen vanilloid-rezeptor vr1 kodiert Withdrawn EP1175504A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29270099A 1999-04-15 1999-04-15
US292700 1999-04-15
PCT/US2000/009897 WO2000063415A1 (en) 1999-04-15 2000-04-13 Dna encoding the human vanilloid receptor vr1

Publications (2)

Publication Number Publication Date
EP1175504A1 EP1175504A1 (de) 2002-01-30
EP1175504A4 true EP1175504A4 (de) 2002-07-31

Family

ID=23125812

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00922143A Withdrawn EP1175504A4 (de) 1999-04-15 2000-04-13 Dna, welche für den menschlichen vanilloid-rezeptor vr1 kodiert

Country Status (5)

Country Link
EP (1) EP1175504A4 (de)
JP (1) JP2003520022A (de)
AU (1) AU4237400A (de)
CA (1) CA2370570A1 (de)
WO (1) WO2000063415A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69819345T2 (de) 1997-08-20 2004-07-15 The Regents Of The University Of California, Oakland Für den capsaicin rezeptor kodierende nukleinsäuresequenzen und dem capsaicin rezeptor ähnliche polypeptide und ihre verwendung
GB9907097D0 (en) 1999-03-26 1999-05-19 Novartis Ag Organic compounds
US6482611B1 (en) 1999-09-23 2002-11-19 Neurogen Corporation Human capsaicin receptor and uses thereof
EP1170365A1 (de) * 2000-07-04 2002-01-09 Smithkline Beecham Plc Ein Mitglied der Ionenkanal Polypeptide Familie; Vanilrep4
ES2300366T3 (es) 2000-09-02 2008-06-16 Grunenthal Gmbh Oligonucleotidos antisentido contra el vr1.
DE10043674A1 (de) * 2000-09-02 2002-03-21 Gruenenthal Gmbh Antisense Oligonukleotide
GB0128161D0 (en) * 2001-11-23 2002-01-16 Merck Sharp & Dohme Receptor protein
RU2392278C2 (ru) 2004-07-15 2010-06-20 Джапан Тобакко Инк. Конденсированное производное бензамида и ингибитор активности подтипа 1 рецептора ваниллоида (vr1)
US7906508B2 (en) 2005-12-28 2011-03-15 Japan Tobacco Inc. 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity
GB201918103D0 (en) * 2019-12-10 2020-01-22 Oblique Therapeutics Ab Epitopes and antibodies
CN111455470A (zh) * 2020-04-09 2020-07-28 嘉兴菲沙基因信息有限公司 一种可以提升Hi-C文库数据质量的小片段DNA文库构建方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009140A1 (en) * 1997-08-20 1999-02-25 The Regents Of The University Of California Nucleic acid sequences encoding capsaicin receptor and capsaicin receptor-related polypeptides and uses thereof
WO1999037675A1 (en) * 1998-01-22 1999-07-29 The Regents Of The University Of California Nucleic acid sequences encoding capsaicin receptors
EP0943683A1 (de) * 1998-03-10 1999-09-22 Smithkline Beecham Plc Menschliches Vanilloid Rezeptorhomolog Vanilrep1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009140A1 (en) * 1997-08-20 1999-02-25 The Regents Of The University Of California Nucleic acid sequences encoding capsaicin receptor and capsaicin receptor-related polypeptides and uses thereof
WO1999037675A1 (en) * 1998-01-22 1999-07-29 The Regents Of The University Of California Nucleic acid sequences encoding capsaicin receptors
EP0943683A1 (de) * 1998-03-10 1999-09-22 Smithkline Beecham Plc Menschliches Vanilloid Rezeptorhomolog Vanilrep1

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0063415A1 *

Also Published As

Publication number Publication date
EP1175504A1 (de) 2002-01-30
WO2000063415A1 (en) 2000-10-26
AU4237400A (en) 2000-11-02
WO2000063415A8 (en) 2001-01-18
JP2003520022A (ja) 2003-07-02
CA2370570A1 (en) 2000-10-26

Similar Documents

Publication Publication Date Title
HUP0201438A2 (en) Dna vaccine - pcv
DE60014382D1 (en) Joystick
GB9913536D0 (en) Use
GB9907812D0 (en) Sequencing
EP1175504A4 (de) Dna, welche für den menschlichen vanilloid-rezeptor vr1 kodiert
IL146151A0 (en) Human-g-protein receptor
EP1100896A4 (de) Snorff33 rezeptor kodierende dna
EP1144628A3 (de) Menschliches vanilloid-rezeptorgen
HK1028566A1 (en) Isolated dna encoding human h3histamine receptor
GB9901622D0 (en) Construction system
EP1242453A4 (de) Für snorf62 und snorf72 rezeptoren kodierende dna
GB2352741B (en) Dome construction
AU6878200A (en) Novel receptors and genes encoding the same
EP1181316A4 (de) DNA, WELCHE FüR SNORF36A- UND SNORF36B-REZEPTOREN KODIERT
GB9905644D0 (en) Dna
GB9816897D0 (en) Therapeutic use
GB9812662D0 (en) Therapeutic use
GB9911238D0 (en) Therapeutic use
GB9821179D0 (en) Therapeutic use
GB9811624D0 (en) Therapeutic use
EP1225220A4 (de) FüR ENDO-BETA-GALAKTOSIDASE KODIERENDE DNS
AU5934800A (en) Dna encoding orphan snorf40 receptor
GB9812664D0 (en) Therapeutic use
GB0002254D0 (en) The care system
TW403036U (en) Improved scissors structure

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011107

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HUVAR, RENE

Inventor name: ROGERS, KATHRYN, E.

Inventor name: ERLANDER, MARK

Inventor name: DUBIN, ADRIENNE

Inventor name: HUVAR, ARNE

A4 Supplementary search report drawn up and despatched

Effective date: 20020619

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20041013

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050224